GAL and melanoma: In addition, non-carbohydrate inhibitors for Gal-1 and Gal-3—notably TD139, GM-CT-01, GM-RD-02, MCP, GCS- 100, anginex, 6DBF7, OTX008, and G3-C12—have shown efficacy in inhibiting tumor growth, angiogenesis, proliferation, and the restoration of T cell surveillance in ovarian, melanoma, breast cancer, lung, head and neck, sarcoma, prostate, multiple myeloma, diffuse large B cell lymphoma, and colon cancers [104,149,152].